



**Trastuzumab
for injection**

(r-DNA origin)

For I.V. Infusion, single-use vial
(Lyophilised powder)

 **Ogivri™**
(trastuzumab) **150 mg**

Manufactured by: M/s. Biocon Limited
Plot Nos. 2, 3, 4 & 5, Phase IV,
Bommasandra-Jigani Link Road,
Bommasandra Post, Bengaluru 560 099, India

Manufactured for:
Mylan Pharmaceuticals Private Limited,
Plot No.1-A/2, MIDC industrial estate,
Taloja, Panvel, Dist. Raigad - 410208,
Maharashtra, India

Imported by:
Meda Pharma (Thailand) Co.,Ltd., **ใช้เฉพาะโรงพยาบาล**
Bangkok, Thailand

Reg No. 1C 15027/61 (NBS)

คำเตือนตามประกาศกระทรวงสาธารณสุข

ยานี้อาจทำให้เกิดอันตรายร้ายแรงได้

ต้องใช้ภายใต้การควบคุมของแพทย์เท่านั้น



**Trastuzumab
for injection**

(r-DNA origin)

For I.V. Infusion, single-use vial
(Lyophilised powder)

 **Ogivri™**
(trastuzumab) **150 mg**



**Trastuzumab
for injection**

(r-DNA origin)

For I.V. Infusion, single-use vial
(Lyophilised powder)

 **Ogivri™**
(trastuzumab) **150 mg**



Composition:
Each pack contains:
Trastuzumab (r-DNA origin) 150 mg, L-Histidine
2.16 mg, L-Histidine Hydrochloride 3.36 mg,
Polyethylene Glycol 3350 (Macrogol 3350),
33.6 mg, D-Sorbitol 115.2 mg

Storage: Store at temperature between 2°C to 8°C.
Reconstitute with 7.2 mL Sterile Water for injection
(not supplied in this pack).

Do not freeze the reconstituted solution.

Use the solution immediately after reconstitution
with SWFI, as it contains no preservatives. If not
used immediately, store the reconstituted solution
for up to 24 hours at 2°C to 8°C (36°F to 46°F);
discard any unused solution after 24 hours.

Keep out of reach of children.

Do not use in case any foreign particulate matter
is observed inside the vial after reconstitution.
Do not accept if vial seal is broken.

Dosage and Administration:
Read enclosed prescribing information sheet
before use.

Trastuzumab:
Mfg Lic No: KTK/28D/7/2006

Batch No.

Mfg Date:

Exp. Date:

ยาสิ้นอายุ